CD33/CLL1 dual CAR-NK cell therapy (Hangzhou Qihan)

N/A

Report date: 2026/02/12 20:00:14

Base Information

Drug NameCD33/CLL1 dual CAR-NK cell therapy (Hangzhou Qihan)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cell replacementsMyeloid cell surface antigen CD33 modulatorsC-Type lectin domain family 12 member A modulators

TargetsMyeloid cell surface antigen CD33C-Type lectin domain family 12 member A

Therapy Area/IndicationsNeoplasm, ResidualLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesHangzhou Qihan Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Qihan Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasm, ResidualLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A